Corporate ActionAug 13, 2026, 04:10 PM
Silexion Therapeutics Raises $2.5M in Public Offering
AI Summary
Silexion Therapeutics Corp. completed a public offering on August 13, 2026, raising approximately $2.5 million in gross proceeds. The offering included ordinary shares, pre-funded warrants, and Series E ordinary warrants at a purchase price of $0.65 per unit. The net proceeds of approximately $2.1 million will be allocated to advancing the company's SIL204 clinical trial and for general corporate purposes.
Key Highlights
- Gross proceeds from the public offering were approximately $2.5 million.
- Net proceeds to Silexion Therapeutics were approximately $2.1 million.
- The offering included 2,028,619 ordinary shares and 1,817,542 pre-funded warrants.
- Additionally, 3,846,161 Series E ordinary warrants were part of the offering.
- The purchase price was $0.65 per share and accompanying ordinary warrants.
- Proceeds will be used to advance the SIL204 clinical trial and for general corporate purposes.
- H.C. Wainwright & Co. received a 7.0% cash fee and a 1.0% management fee.
- Placement Agent Warrants for 269,231 ordinary shares were issued to the agent.
Price Impact
More from SLXN